Plenaxis (abarelix), a new drug for advanced prostate cancer
January 2004
Some men will be put on Plenaxis (abarelix), a new drug for advanced prostate cancer.
Plenaxis suppresses testosterone by blocking gonadotropin- releasing hormone receptors. It doesn't cause an initial testosterone surge...like Lupron and other gonadotropin agonists.
But Plenaxis has a serious drawback...it causes life-threatening allergic reactions in almost 4% of patients.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote